HTT-1A Modulation Oligonucleotides via dsRNA Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Huntington's disease (HD) fail to effectively counteract the neurodegenerative effects of the HTT-1A variant, which is a highly pathogenic fragment of the huntingtin protein associated with the progression of HD.
Innovation Solution
Development of double-stranded RNA (dsRNA) molecules with antisense strands complementary to specific HTT-1A nucleic acid sequences, designed to inhibit the expression of the HTT-1A gene by targeting and degrading its mRNA, thereby reducing its neurodegenerative impact.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Huntington's disease are used, then general HD symptoms may be managed, but the neurodegenerative effects of the HTT-1A variant cannot be effectively counteracted
Solution Approach 1:
The patent applies local quality by designing oligonucleotides with specific sequences that target only the HTT-1A variant mRNA. The antisense strands are engineered to be complementary to specific regions of the HTT-1A transcript, allowing selective binding and degradation of this pathogenic variant while leaving other HTT isoforms and normal cellular processes unaffected. This sequence-specific targeting resolves the contradiction between general treatment effectiveness and specificity to the HTT-1A variant.
Solution Approach 2:
The patent segments the huntingtin gene expression pathway by introducing oligonucleotides that specifically interfere with HTT-1A mRNA processing and translation. The double-stranded RNA structures are designed to bind to specific segments of the HTT-1A transcript, particularly targeting the exon 1-intron 1 junction region, thereby selectively disrupting this pathogenic isoform's expression without affecting the overall HTT protein function needed for normal cellular processes.
2Reliability
If oligonucleotides are designed to target HTT-1A specifically, then HTT-1A expression can be inhibited, but the complexity of the molecule increases
Solution Approach 1:
The patent employs composite materials by constructing double-stranded RNA oligonucleotides with chemically modified nucleotides. The molecules combine antisense RNA strands complementary to HTT-1A sequences with modified ribose sugars (such as 2'-O-methyl or 2'-fluoro modifications) and phosphorothioate backbone linkages. This composite structure provides both high affinity binding to HTT-1A mRNA for effective inhibition and enhanced stability against nucleases, while the modular design allows optimization of each component to balance efficacy with manageable complexity.
3Reliability
If dsRNA molecules are used to inhibit HTT-1A mRNA, then gene expression is significantly inhibited, but the difficulty of delivering the molecule to target tissues increases
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical properties of the dsRNA oligonucleotides to improve delivery. Chemical modifications including 2'-O-methyl and 2'-fluoro ribose modifications, along with phosphorothioate backbone linkages, alter the molecule's stability, charge distribution, and resistance to degradation. These parameter changes enable the oligonucleotides to withstand harsh delivery conditions, resist enzymatic degradation in circulation, and maintain structural integrity when reaching target tissues such as the brain, thereby facilitating effective delivery while maintaining high gene expression inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA molecules significantly inhibit HTT-1A gene expression, potentially slowing or halting the progression of HD by reducing the levels of the HTT-1A protein in targeted tissues such as the hippocampus and cortex.
Implementation Method 1
the antisense strand comprises a sequence substantially complementary to a HTT nucleic acid sequence
Data Source
AI summary
This disclosure relates to novel HTT-1A targeting sequences. Novel HTT-1A targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.